ZS Pharma

Committed to Advancing Patient Care

  • Developing New Therapies to Improve the Treatment of HyperkalemiaThe core of our R&D program is to develop safe and efficacious treatments for patients with serious conditions using a novel selective ion-trap technology
  • Partnering with Clinicians to Advance Hyperkalemia TreatmentZS Pharma is committed to improving patient outcomes by developing novel therapies to treat life-threatening conditions, such as hyperkalemia
  • Our Commitment to the PatientZS Pharma is committed to improving patient outcomes and care by developing novel therapies to treat and manage hyperkalemia
Developing New Therapies to Improve the Treatment of Hyperkalemia1 Partnering with Clinicians to Advance Hyperkalemia Treatment2 Our Commitment to the Patient3

Our Commitment

ZS Pharma is a biopharmaceutical company committed to the development and commercialization of highly selective, non-absorbed drugs to treat renal, cardiovascular, liver and metabolic diseases. Our initial focus is on the development of ZS-9, our product candidate in Phase 3 development for the treatment of hyperkalemia, a life-threatening condition characterized by abnormally high levels of potassium in the blood.

We are advancing ZS-9 through clinical development with the goal of obtaining approval for the treatment of acute and chronic hyperkalemia, regardless of the underlying disease state. Learn more about the results from our pivotal Phase 3 clinical trial in patients with hyperkalemia here.

Stay in the Know

Keep up to date with the latest ZS Pharma News and Updates

Sign Up

 

Recent News

July 17, 2014

ZS Pharma Secures $20 Million in Debt Financing

Download PDF

July 14, 2014

ZS Pharma Completes Patient Enrollment in ZS004, Its Second Phase 3 Study of ZS-9 in Patients with Hyperkalemia

Download PDF

July 8, 2014

ZS Pharma Announces Allowance of Two U.S. Patent Applications for ZS-9

Download PDF
X

Keep up to date with the latest ZS Pharma News and Updates